English
Language31 languages
EnglishEnglishDeutschGermanالعربيةArabicFrançaisFrenchEspañolSpanishPortuguês (Brasil)Brazilian PortugueseItalianoItalian日本語Japanese한국어KoreanРусскийRussianTürkçeTurkishفارسیPersian (Farsi)עבריתHebrewҚазақшаKazakhPolskiPolishNederlandsDutchRomânăRomanianČeštinaCzechΕλληνικάGreekMagyarHungarianBahasa IndonesiaIndonesianहिन्दीHindiاردوUrduBahasa MelayuMalayไทยThaiУкраїнськаUkrainianO‘zbekchaUzbekTiếng ViệtVietnamese繁體中文Traditional ChineseDanskDanishSvenskaSwedish

Supported languages are prioritized from the country mix of past inquiries. If you would like another language, please send us feedback.

Recent Confirmed OrdersLast 7 days
Australia2 gTirzepatide 100 mg · CagriSema 20 mg · BPC-157 10 mg · TB-500 5 mg · Melanotan II 10 mg · PT-141 10 mg · Bacteriostatic Water 3 ml
View all

Repair and regenerative research

GLOW (BPC+GHK-Cu+TB)

Unvalidated Three-Component Research Blend / BPC-157 + TB-500 Fragment + GHK-Cu

Per batch COACAS 137525-51-0RUO
Research statusCombination Unstudied / Components Have Unequal Evidence
Supplied formMulti-component peptide/copper research formulation
Lead timeConfirmed with quote
GLOW (BPC+GHK-Cu+TB) — Lyophilized material; confirm released-lot appearance on the COA
GLOW (BPC+GHK-Cu+TB) — Lyophilized material; confirm released-lot appearance on the COA · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • The defensible B2B value is a defined analytical mixture for component-identity, ratio, compatibility, degradation and cell-model research
  • Regeneration, wound healing, tendon recovery, anti-inflammatory, collagen, anti-ageing and 'glow' claims are extrapolated from unequal component evidence and have not been demonstrated for this blend
  • Combining three speculative benefit narratives does not create evidence of additive or synergistic efficacy.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
137525-51-0
Formula
Not applicable — mixture or multi-component material
Molecular weight
Component-specific; no single molecular weight
Appearance
Lyophilized material; confirm released-lot appearance on the COA
Purity
Per batch COA
Storage
Follow component-form and lot-specific stability data. BPC-157 free base versus acetate, Ac-LKKTETQ, and the selected GHK-to-copper complex have different critical attributes. Verify blend homogeneity, peptide recovery, copper stoichiometry, aggregation, oxidation, light sensitivity and temperature-excursion stability rather than applying one generic storage rule.
MOQ
On request
Lead time
Confirmed with quote

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about GLOW (BPC+GHK-Cu+TB)

GLOW is a non-standardized marketing name for a physical mixture of BPC-157, the N-acetylated thymosin-beta4 17-23 fragment Ac-LKKTETQ commonly called TB-500, and a GHK-copper complex. No peer-reviewed human or controlled preclinical study of the three-component fixed combination was identified. Evidence for full-length thymosin-beta4 cannot be transferred to the seven-residue TB-500 fragment, and topical or in vitro GHK-Cu evidence cannot validate an injectable mixture. The blend has no single molecular identity, CAS number, molecular weight, pharmacokinetic profile or proven synergy.

  • Appropriate work includes component-specific identity and content testing, blend-uniformity studies, copper coordination and free-copper analysis, compatibility and forced-degradation studies, analytical-method development and controlled cell assays
  • Skin rejuvenation, procedural recovery, tendon repair and systemic wellness are marketing or extrapolated hypotheses, not established indications for the mixture.

Mechanism context

The question the literature is testing

BPC-157 research is predominantly preclinical and its molecular targets remain incompletely defined. Ac-LKKTETQ is derived from the actin-binding region of full-length thymosin-beta4, but the fragment's biological effects and human exposure are poorly documented. GHK-Cu has in vitro and topical-cosmetic literature involving copper transport, extracellular-matrix and wound-response pathways. These separate observations do not demonstrate that the components remain chemically compatible, reach relevant targets or act additively in one lyophilized mixture.

Evidence map

Research routes and exposure context

Evidence tierAnalytical / laboratory context
Routes reported in sources
No administration route applies
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • No human safety dataset exists for the fixed combination
  • FDA identifies significant compounding safety risks for BPC-157, TB-500/thymosin-beta4 fragment and injectable GHK-Cu, including immunogenicity from aggregation or peptide-related impurities and limited or absent human exposure data
  • FDA briefing documents dated May 11 and May 15, 2026 propose not adding BPC-157 free base or acetate and TB-500 free base or acetate, respectively, to the 503A Bulks List
  • Both substance groups are scheduled for PCAC discussion on July 23, 2026; a briefing proposal or committee discussion is not a final FDA determination, approval or authorization
  • WADA's 2026 Prohibited List names BPC-157 under non-approved substances and names TB-500/thymosin-beta4 in the growth-factor section, prohibited at all times
  • This RUO blend is not qualified for injection, and blue colour or local discolouration is not a safety test.

Interactions reported in the literature

  • No validated compatibility or interaction matrix exists for the three components or for NAD+, vitamin C, retinoids, acids, iron chelators, standalone peptides or copper supplements
  • Copper can alter oxidation, coordination, chromatography and peptide stability
  • Test the complete matrix under intended analytical conditions; vendor stack lists and user reports are not interaction evidence.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

GLOW (BPC+GHK-Cu+TB) factory batch COAs

GLOW (BPC+GHK-Cu+TB) 70 mg Factory batch COA protected previewGLOW (BPC+GHK-Cu+TB)70 mg · WHJLP-GLOW70-260528-D
Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

  • The COA must state each component's chemical form, sequence, terminal modifications, target and measured content, mass balance and ratio
  • Require high-resolution intact mass plus MS/MS or mapping for each peptide, chromatographic purity and identified impurity profiles, blend uniformity, BPC-157 acetate and water, TB-500 acetylation, GHK assay, copper by ICP-MS or equivalent, GHK:copper stoichiometry, free or labile copper, oxidation, aggregates, residual solvents, bioburden, endotoxin and lot stability
  • A total 70 mg claim, one BPC-157 mass, nominal HPLC purity, pale-blue colour or clear solution cannot release this mixture.
Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
GLOW-70MG70 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow component-form and lot-specific stability data. BPC-157 free base versus acetate, Ac-LKKTETQ, and the selected GHK-to-copper complex have different critical attributes. Verify blend homogeneity, peptide recovery, copper stoichiometry, aggregation, oxidation, light sensitivity and temperature-excursion stability rather than applying one generic storage rule.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • FDA's May 11, 2026 BPC-157 and May 15, 2026 TB-500 evaluations document inconsistent substance identification, inadequate characterization, insufficient or absent human evidence, immunogenicity concerns and proposals against 503A listing. FDA's significant-safety-risk page separately addresses BPC-157, TB-500 fragment and injectable GHK-Cu. Xu 2022 provides animal BPC-157 PK only. Ho 2012 and later metabolism work establish Ac-LKKTETQ detection, not human benefit. Full-length thymosin-beta4 trials are not TB-500-fragment trials. GHK-Cu reviews mainly summarize in vitro and topical evidence. No qualifying study of the three-component GLOW blend was identified.
  1. 01

    Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT)

    Inflammopharmacology · 2025 · peer-reviewed commentary/critical review

    Open source
  2. 02

    The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity

    CNS Neuroscience & Therapeutics (PMC) · 2024 · peer-reviewed narrative review

    Open source
  3. 03

    Distribution, Metabolism, Excretion, and Pharmacokinetics of the Gastric Pentadecapeptide BPC157 in Rats and Dogs

    Frontiers in Pharmacology · 2022 · peer-reviewed animal pharmacokinetic study

    Open source
  4. 04

    Thymosin beta4 Promotes Dermal Healing

    Vitamins & Hormones · 2016 · peer-reviewed book chapter/review

    Open source
  5. 05

    Study of Thymosin Beta 4 in Patients With Pressure Ulcers

    ClinicalTrials.gov (U.S. National Library of Medicine trial registry) · 2006 · clinical trial registry entry (Phase 2)

    Open source
  6. 06

    Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review

    Applied Sciences (MDPI) · 2026 · peer-reviewed scoping review

    Open source
  7. 07

    GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

    BioMed Research International · 2015 · peer-reviewed review

    Open source
  8. 08

    Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

    FDA · 2026 · U.S. government regulatory safety information

    Open source

Product FAQ

Questions buyers ask about GLOW (BPC+GHK-Cu+TB)

How should a fixed GLOW blend be qualified before purchase?+

Treat it as a multi-component formulation, not as one peptide with one purity value. The order specification should state the exact BPC-157 form, the exact Ac-LKKTETQ sequence and termini, the selected GHK-to-copper complex and copper stoichiometry, the target amount of each component and the blending tolerance. The batch plan should define component-specific identity and content methods, blend-homogeneity sampling, free or unbound copper where relevant, water and appearance, and stability-indicating checks for oxidation, aggregation and peptide recovery.

Why is a single HPLC purity percentage insufficient for this blend?+

The three components can have different chromatographic retention, detector response, copper-dependent behavior and degradation pathways. One area-percent result may describe only one method and cannot prove the amount, identity or uniform distribution of every component. A useful COA separates component identity from chromatographic purity, component content, copper stoichiometry and blend homogeneity, and links each result to a named method and acceptance limit.

Related research materials

Compare adjacent molecules and documentation needs.

Full catalog
Repair and regenerative research

GHK-Cu

Copper(II)-complexed GHK tripeptide · supplied form and copper stoichiometry are procurement-critical

Purity
Lot-specific · Batch COA
CAS
89030-95-5
Latest batch COA available on request
Repair and regenerative research

TB-500

N-acetylated LKKTETQ thymosin-β4 fragment research reference

Purity
Lot-specific · Batch COA
CAS
885340-08-9
Latest batch COA available on request
Repair and regenerative research

TB500 Fragment (Frag 17-23)

N-acetylated thymosin-β4 residues 17–23 research fragment · not full-length thymosin-β4

Purity
Lot-specific · Batch COA
CAS
885340-08-9
Latest batch COA available on request
Repair and regenerative research

PEG-MGF

PEG-conjugated MGF E-peptide research material · architecture must be defined by lot

Purity
Lot-specific · Batch COA
CAS
108174-48-7
Latest batch COA available on request